Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis

NCT02460068 is registered in ClinicalTrials.gov with Italian Network for Tumor Biotherapy Foundation as lead sponsor.

NCT NCT02460068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02460068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis
Lead sponsor
Italian Network for Tumor Biotherapy Foundation
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2012
Completion date
January 31, 2020
Enrollment
168 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases